---
title: mutations useful as clonal markers and dx tools of myeloproliferative neoplasms
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[overview of myeloproliferative neoplasms]]

# mutations useful as clonal markers and dx tools of myeloproliferative neoplasms

Gain of fxn mutations inÂ **_JAK2_**Â V617F (Janus kinase) frequently present (PV ~95%, ET ~50%, PMF ~50%;Â NEJMÂ 2005;352:1779)

**_BCR-ABL1_**Â fusion inÂ **all**Â cases of CML;Â **_SETBP1_**Â in aCML

**_CALR_**Â exon 9 mutation, type I and II (most MPNs w/oÂ _JAK2_Â orÂ _MPL_Â mutation, including ~25% of ET, ~35% of myelofibrosis Pts;Â NEJMÂ 2013;369:2379 & 2391)

Type I has better prognosis.

**_MPL_**,Â **_TET2, & ASXL1_**Â mutation w/ lower frequency

**_CSF3R_**Â mutation present in ~60% of CNL;Â **_KIT_**Â D816V in 90% of systemic mastocytosis

